Original Article

High Value of Combined Serum C-Reactive Protein and BODE Score for Mortality Prediction in Patients With Stable COPD

Shih-Feng Liu,a,b Chin-Chou Wang,a Chien-Hung Chin,a Yung-Che Chen,a Meng-Chih Lin,a,b,*

a Division of Pulmonary & Critical Care Medicine, Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Taiwan, China
b Chang Gung University College of Medicine, Taiwan, China

ARTICLE INFO

Article history:
Received 9 December 2010
Accepted 18 April 2011
Available online 9 November 2011

Keywords:
Chronic obstructive pulmonary disease
BODE score
C-reactive protein

ABSTRACT

Introduction: Both BODE score (body mass index, degree of airflow obstruction, functional dyspnea, and exercise capacity) and serum C-reactive protein (CRP) are validated predictors of mortality in patients with chronic obstructive pulmonary disease (COPD). The aim of this study is to investigate the predictive value of combined serum CRP and BODE score for mortality in COPD patients.

Patients and methods: A cohort of 114 clinically stable COPD patients was assessed for predictors of longitudinal mortality. Variables included age, gender, current smoking status, pack-years, maximal inspiratory/expiratory pressure, BODE score (body mass index, degree of airflow obstruction, functional dyspnea, and exercise capacity), serum CRP, and fibrinogen. Predictors were assessed by Cox proportional hazards regression model. Survival was estimated by Kaplan–Meier method and log-rank test.

Results: Serum CRP (P=0.005; HR=1.042; 95% CI=1.019–1.066) and BODE score (P=0.032; HR=1.333; 95% CI=1.025–1.734) were independent predictors of survival in the multivariate analysis. The cumulative survival rates of COPD patients were sorted from the worst to the best as following: serum CRP>3 mg/l and quartile 3–4; serum CRP>3 mg/l and quartile 1–2; serum CRP≤3 mg/l and quartile 3–4; serum CRP≤3 mg/l and quartile 1–2 (P<0.001).

Conclusions: Serum CRP and BODE score are independent predictors of survival in stable COPD patients. Combination of serum CRP and BODE score has higher predictive value in clinical practice.

Alto valor de la combinación de la concentración sérica de proteína C reactiva y la puntuación BODE para la predicción de la mortalidad en pacientes con EPOC estable

RESUMEN

Introducción: Tanto la puntuación BODE (Índice de masa corporal, grado de obstrucción del flujo aéreo, disnea funcional y capacidad de ejercicio) como la concentración sérica de proteína C reactiva (PCR) son variables pronósticas validadas de mortalidad en pacientes con enfermedad pulmonar obstructiva crónica (EPOC). El objetivo del presente estudio fue investigar el valor predictivo de la combinación de la concentración sérica de PCR y la puntuación BODE para la mortalidad en pacientes con EPOC.

Pacientes y métodos: Se evaluó una cohorte de 114 pacientes con EPOC, clínicamente estables, en busca de las variables pronósticas de mortalidad longitudinal. Las variables incluyeron edad, sexo, tabaquismo actual, paquetes-ano, presión inspiratoria/expiratoria máxima, puntuación BODE (body mass index, degree of airflow obstruction, functional dyspnea, and exercise capacity), concentración sérica de PCR y fibrinógeno. Las variables pronósticas se evaluaron mediante un modelo de regresión de riesgos proporcionales de Cox. La supervivencia se estimó mediante el método de Kaplan–Meier y la prueba del log-rank.

Resultados: La concentración sérica de PCR (P=0.005; CR=1.042; IC del 95%:1.019–1.066) y la puntuación BODE (P=0.032; CR=1.333; IC del 95%:1.025–1.734) fueron variables pronósticas independientes de la supervivencia en el análisis multivariante. Las tasas de supervivencia acumulativas de los pacientes con
Introduction

Chronic obstructive pulmonary disease (COPD) is an inflammatory process characterized by progressive airflow limitation and the destruction of the parenchyma. This disease not only affects the lungs but may also produce substantial systemic effects. C-reactive protein (CRP) is an important systemic inflammation marker that reflects the total systemic inflammation load. It has been demonstrated that its concentration is high in patients with stable COPD and during exacerbations. It is also a prognostic variable for hospitalization and mortality in patients with chronic respiratory failure. An increase in its concentration can predict cardiovascular risk in patients with COPD. Two epidemiological studies have demonstrated that the increase in its concentration is independently associated with overall and cardiovascular mortality in patients with the disease and mild or moderate degrees of obstruction of the airways.

Celi et al. proposed the BODE index, a multidimensional parameter that includes body mass index (B), degree of airflow obstruction (O), functional dyspnea (D) and exercise capacity (E). It was reported to be better than forced expiratory volume in 1 s (FEV₁) to reflect the severity of COPD, and it is effective in the prediction of mortality in patients with the disease. In this population of patients, it has also been described that the BODE score is applicable for predicting an individual’s need for hospitalization, determining the lung function changes of the follow-up during pulmonary rehabilitation and the transbronchoscopic application of one-way valves, predicting survival after lung volume reduction surgery and reflecting modifications of the disease.

In clinical practice, it is foreseeable that the combination of the levels of serum CRP concentrations and the BODE score would be a better predictor for survival between patients with COPD, because serum CRP is an important systemic inflammatory marker and the BODE score is a clinical parameter of great use for patients with the disease. The objective of the present study was to determine the predictive value of CRP serum concentrations combined with the BODE score for mortality in patients with stable COPD.

Materials and Methods

Study Design

We carried out a prospective study to select clinically stable COPD patients and register their characteristics in order to identify the prognostic longitudinal mortality variables. The variables included age, sex, current tobacco use, pack-years, maximal inspiratory pressure, maximal expiratory pressure, severity of COPD, modified Medical Research Council dyspnea scale (MMRC), body mass index, diffusion capacity, 6-minute walk test (6MWT), serum CRP concentration, serum fibrinogen concentration and BODE score.

Study Subjects

The study was approved by the Research Committee of the Chang Gung Memorial Hospital, which also provided financing. A total of 125 patients were consecutively selected with variable COPD severity from April 2005 to July 2006 from the Division of Pulmonary Medicine outpatient clinic, Chang Gung Memorial Hospital-Kaohsiung Medical Center, a hospital with 2300 primary-care beds and a tertiary referral center in Taiwan (China). These patients underwent spirometry and lung volume determinations in accordance with the recommendations published by the American Thoracic Society and according to standard references. Each recruited COPD patient was over the age of 40 and had been a heavy smoker, with smoking histories of at least 10 pack-years. The diagnosis of COPD was established based on anamnesis, physical exploration and the spirometric data of the patient indicative of a post-bronchodilator FEV₁ (forced expiratory volume in 1 s)/forced vital capacity (FVC) ratio of less than 0.7, with a reversibility by means of inhaled bronchodilator of FEV₁ <15%.

In the selected patients, other causes of airway limitation were excluded, such as pulmonary tuberculosis, bronchial asthma, bronchiectasis and heart failure, identified by reviewing chest radiographies and medical files. We also excluded those patients with diagnosis of cardiovascular disease, such as coronary artery disease, peripheral vasculopathy or cerebral vascular disease. After 6 weeks of appropriate treatment, the patients with clinically stable COPD were included; for these patients, the BODE index was calculated and serum CRP concentrations determined. The patients who experienced an exacerbation in their COPD (fever, increase in purulent sputum or dyspnea) or hospitalizations for any reason during the 6-week treatment period were excluded from the study. After their inclusion, the patients were seen every 3 months based on the medical histories and the computerized information. If a patient was lost to follow-up at our hospital, the research assistant communicated with the patient or his/her family and acquired information regarding mortality in a telephone interview. The final data of the study were collected on 7 August 2008. During the follow-up period, the mortality due to any cause was used as an analyzed variable.

CRP Determination

Fasting blood samples were obtained while the patients were at rest and before carrying out any other test. The CRP concentrations were determined with a high-sensitivity immunoanalysis. The analytical sensitivity of this analysis was 0.1 mg/l, and the determination range was 0.1–20 mg/l. We divided the COPD patients into two subgroups with an initial cut value for the CRP concentration >3 mg/l or ≤3 mg/l because, in studies published about cardiovascular medicine, and in the COPD cohort described by Dahl et al., it has been previously demonstrated that this value is a determinant for patient survival.

Evaluation With the BODE Index

Each patient was assigned a BODE score, which was calculated using an empirical model as has previously been described. The body mass index (BMI) was calculated as the weight of the patient in kilograms divided by height in meters squared. The degree of airflow obstruction was determined by means of FEV₁, dyspnea was determined using the MMRC dyspnea scale and exercise capacity was determined with the distance walked in 6 minutes.
and quartile 3, 5–6 points; and quartile 4, 7–10 points. Statistical Analyses

The continuous variables are presented as means ± standard deviation and the categorical variables are presented as absolute numbers and percentages. The relationship between the BODE quartile and the patients with a serum concentration of CRP >3 mg/l was analyzed by means of a non-parametric test. The difference in the BODE scores between patients with a serum CRP concentration >3 mg/l and ≤3 mg/l was evaluated using the Student’s t-test. In order to identify the most significant prognostic factors for survival and calculate the hazard ratios (HR) for mortality and the 95% confidence intervals (CI), we used a Cox proportional hazards regression model. The variables whose P values were <0.05 in the univariate analysis were also analyzed in a multivariate analysis. Survival was estimated by means of the Kaplan–Meier method with a log-rank test. A two-tailed P value<0.05 was considered statistically significant. The statistical analyses were done using the SPSS program (version 13.0; SPSS Inc., Chicago, IL, United States).

Results

Characteristics of the Study Participants

We initially selected 125 patients for the present study. However, 6 of them were excluded due to the exacerbation of the symptoms or to hospitalization during the initial 6-week observational period. Out of the 119 cases included in the study, we could not obtain information about the mortality in 5 because they had either changed residence or telephone, or due to the lack of cooperation of the patient or his/her family. Therefore, in the final analysis we include a total of 114 patients. Table 1 shows the characteristics of the study participants.

Correlation Between the Serum Concentration of CRP and the BODE Score

There were no significant differences in the BODE scores between patients whose serum CRP concentrations were ≤3 mg/l and those in whom it was >3 mg/l (3.11 compared with 3.34; P=0.62). The non-parametric analysis also did not demonstrate a correlation between the BODE quartile and the serum concentration of CRP (P=0.87).

Predictive Variables for Survival in Patients With Chronic Obstructive Pulmonary Disease

In the univariate analysis, it was demonstrated that parameters such as age, FEV1/FVC, MMRC dyspnea scale, 6MWT, serum concentration of CRP, carbon monoxide diffusion capacity (DLCO), maximum inspiratory pressure (PImax) and BODE scores were significantly associated with mortality (Table 2). However, despite treating the serum concentration of CRP with either total data or divided by categories, or treating the BODE score as either a continuous variable or divided in quartile categories, the multivariate analysis demonstrated that the serum CRP concentration and the BODE scores were independent prognostic variables for mortality (6MWT). For each value of FEV1, MMRC dyspnea scale and 6MWT, each patient received points that varied from 0 to 3; for the body mass index, each patient received 0 or 1 point. The points for each component of the BODE index were added, and the score varied between 0 and 10 points for each patient. In addition, the BODE score was classified in quartiles as previously described: quartile 1 included patients with a score of 0–2; quartile 2, 3–4 points; quartile 3, 5–6 points; and quartile 4, 7–10 points.

Survival of Patients With Chronic Obstructive Pulmonary Disease

During the periods of the present study, 17 (14.9%) patients died (17/114). In patients with clinically stable COPD and a serum CRP concentration >3 mg/l, we identified a lower accumulative survival rate than in those with a value ≤3 mg/l (P=0.003) (Fig. 1). In the subgroup with a concentration of CRP >3 mg/l, there was a mortality rate of 27% (12/44) during the study period. In comparison, in the group with values ≤3 mg/l, the mortality rate was 6.3% (4/63). In patients with a BODE score in quartile 3–4, there was a lower accumulative survival rate than in those with a BODE score in quartile 1–2 (P=0.02) (Fig. 2). In the subgroup of quartile 3–4, there was a mortality rate of 27% (10/37) during the study period. In comparison, the mortality rate of the subgroup of quartile 1–2 was 9.1% (7/77). The accumulative survival rates of the COPD patients were classified from the worst to the best in the following manner: serum CRP concentration >3 mg/l and quartile 3–4; serum CRP concentration >3 mg/l and quartile 1–2; serum CRP concentration ≤3 mg/l and quartile 3–4; serum CRP concentration ≤3 mg/l and quartile 1–2 (P=0.001) (Fig. 3). The mortality rates of the COPD subgroups during the study period were likewise classified: serum CRP concentration >3 mg/l and ≤3 mg/l.

Table 1: Characteristics of the 114 Patients With Clinically Stable Chronic Obstructive Pulmonary Disease.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>69.6 ± 10.3</td>
</tr>
<tr>
<td>Males, %</td>
<td>111/114 (97.4)</td>
</tr>
<tr>
<td>Smoking history, pack-years</td>
<td>57.6 ± 31.9</td>
</tr>
<tr>
<td>Current smokers, %</td>
<td>37/114 (32.5)</td>
</tr>
<tr>
<td>FEV1/FVC % reference value</td>
<td>71.6 ± 19.2</td>
</tr>
<tr>
<td>FEV1, % reference value</td>
<td>54.0 ± 11.5</td>
</tr>
<tr>
<td>FEV1, % reference value</td>
<td>53.2 ± 21.4</td>
</tr>
<tr>
<td>COPD severity according to the classification of the GOLD initiative</td>
<td>mild/moderate/severe/very severe 11/40/37/17</td>
</tr>
<tr>
<td>MMRC dyspnea scale</td>
<td></td>
</tr>
<tr>
<td>≤0–2/3–4</td>
<td>71/43</td>
</tr>
<tr>
<td>6-minute walk test distance, m</td>
<td>402.4 ± 111.1</td>
</tr>
<tr>
<td>Body mass index, BMI</td>
<td>23.5 ± 3.6</td>
</tr>
<tr>
<td>BODE score</td>
<td>3.2 ± 2.3</td>
</tr>
<tr>
<td>Quartile 1/2/3/4</td>
<td>51/26/25/12</td>
</tr>
<tr>
<td>Serum HS-CRP concentration ≤3 mg/l/ &gt;3 mg/l</td>
<td>96/18 (1/5, 0.16–2.92)</td>
</tr>
<tr>
<td>compared to 5.54</td>
<td>3.1–98.4) mg/l</td>
</tr>
<tr>
<td>Serum fibrinogen</td>
<td>308.6 ± 78.3</td>
</tr>
<tr>
<td>Maximum inspiratory pressure, mm Hg</td>
<td>–55.2 ± 6.6</td>
</tr>
<tr>
<td>Maximum expiratory pressure, mm Hg</td>
<td>98.5 ± 3.2</td>
</tr>
<tr>
<td>DLCO, %</td>
<td>72.2 ± 24.1</td>
</tr>
</tbody>
</table>

FVC, forced vital capacity; FEV1, maximum expiratory volume in 1 s; COPD, chronic obstructive pulmonary disease; BODE, body mass index, degree of airflow obstruction, functional dyspnea and exercise capacity; MMRC, modified Medical Research Council dyspnea scale; 6MWT, 6-minute walk test; DLCO, carbon monoxide diffusion capacity; HS-CRP, high-sensitivity C-reactive protein; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

a The scores of the modified Medical Research Council dyspnea scale (MMRC) may vary from 0 to 4; a score of 4 indicates that the patient experiences too much dyspnea to leave the home or experiences dyspnea while getting dressed/undressed.

b The body mass index is calculated as weight in kilograms divided by height in meters squared.

c Quartile 1 referred to the BODE score from 0 to 2, quartile 2 referred to scores 3 and 4, quartile 3 referred to scores 5 and 6, and quartile 4 referred to scores from 7 to 10.
Table 2

Univariate Analysis of the Prognostic Factors of Patients With Chronic Obstructive Pulmonary Disease.

<table>
<thead>
<tr>
<th>Variables</th>
<th>Odds ratio or exp (B)</th>
<th>95% CI</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>1.07</td>
<td>1.008–1.125</td>
<td>.03</td>
</tr>
<tr>
<td>Current smoker</td>
<td>1.35</td>
<td>0.436–4.122</td>
<td>.61</td>
</tr>
<tr>
<td>Pack-years</td>
<td>0.99</td>
<td>0.969–1.007</td>
<td>.22</td>
</tr>
<tr>
<td>FEV1/FVC, %</td>
<td>0.95</td>
<td>0.908–1.000</td>
<td>.05</td>
</tr>
<tr>
<td>FEV1, 5 reference value</td>
<td>0.99</td>
<td>0.906–1.017</td>
<td>.49</td>
</tr>
<tr>
<td>COPD severity according to the GOLD initiative</td>
<td>1.26</td>
<td>0.479–3.314</td>
<td>.60</td>
</tr>
<tr>
<td>Serum concentration of HS-CRP</td>
<td>≤3 mg/l</td>
<td>quartile 1–2</td>
<td></td>
</tr>
<tr>
<td>MMRC dyspneascale (3–4 compared with 0–2)</td>
<td>3.12</td>
<td>1.15–8.439</td>
<td>.03</td>
</tr>
<tr>
<td>BMI</td>
<td>0.91</td>
<td>0.787–1.057</td>
<td>.22</td>
</tr>
<tr>
<td>DLCO, %</td>
<td>0.97</td>
<td>0.947–0.990</td>
<td>.004</td>
</tr>
<tr>
<td>Serum concentration of HS-CRP</td>
<td>&gt;3 compared with ≤3 mg/l</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serum concentration of HS-CRP</td>
<td>1.04</td>
<td>1.019–1.065</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Serum fibrinogen</td>
<td>1.003</td>
<td>0.997–1.009</td>
<td>.31</td>
</tr>
<tr>
<td>Pmax</td>
<td>0.99</td>
<td>0.987–1.000</td>
<td>.04</td>
</tr>
<tr>
<td>6MWT, m</td>
<td>0.995</td>
<td>0.992–0.999</td>
<td>.02</td>
</tr>
<tr>
<td>BODE score</td>
<td>1.31</td>
<td>1.074–1.598</td>
<td>.008</td>
</tr>
<tr>
<td>BODE score in quartiles</td>
<td>3–4 compared with 1–2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FEV1, maximum expiratory volume in 1 s; COPD, chronic obstructive pulmonary disease; BODE, body mass index, degree of airflow obstruction, functional dyspnea and exercise capacity; CI, confidence interval; MMRC, modified Medical Research Council dyspnea scale; 6MWT, 6-minute walk test; DLCO, carbon monoxide diffusion capacity; HS-CRP, high-sensitivity C-reactive protein; GOLD, Global Initiative for Chronic Obstructive Lung Disease.

Table 3

Multivariate Analysis of the Prognostic Factors of Patients With Stable Chronic Obstructive Pulmonary Disease.

<table>
<thead>
<tr>
<th>Variables</th>
<th>P Value</th>
<th>Odds Ratio or exp (B)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BODE score</td>
<td>.032</td>
<td>1.333</td>
<td>1.025–1.734</td>
</tr>
<tr>
<td>Serum concentration of HS-CRP</td>
<td>&lt;.001</td>
<td>1.042</td>
<td>1.019–1.066</td>
</tr>
<tr>
<td>Model 2</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BODE score in quartile 3–4</td>
<td>.028</td>
<td>3.04</td>
<td>1.130–8.188</td>
</tr>
<tr>
<td>Serum concentration of CRP</td>
<td>&lt;.001</td>
<td>5.15</td>
<td>1.654–16.601</td>
</tr>
</tbody>
</table>

BODE, body mass index, degree of airflow obstruction, functional dyspnea and exercise capacity; HS-CRP, high-sensitivity C-reactive protein; CI, confidence interval

Table 4

Combination of a Serum Concentration of CRP >3 and a BODE Score in Quartile 3–4: Predictive Value for Mortality in Patients With Stable Chronic Obstructive Pulmonary Disease.

<table>
<thead>
<tr>
<th>Variables</th>
<th>P Value</th>
<th>Odds ratio or exp (B)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum concentration of HS-CRP</td>
<td>&lt;.001</td>
<td>6.91</td>
<td>2.565–18.599</td>
</tr>
<tr>
<td>BODE score in quartile 3–4</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BODE, body mass index, degree of airflow obstruction, functional dyspnea and exercise capacity; HS-CRP, high-sensitivity C-reactive protein; CI, confidence interval

Fig. 1. In clinically stable COPD patients whose serum CRP concentration was >3 mg/l, there was a lower cumulative survival rate than in those with levels ≤3 mg/l (P = .001).

Fig. 2. In patients with clinically stable COPD with BODE scores in quartile 3–4, there was a lower accumulative survival rate than in those with a score in quartile 1–2 (P = .02).
patients with initial CRP values >3 mg/l or 

tion correlated with various clinical parameters, including FEV1, 

between the concentration and other clinical variables in patients 

CRP concentrations and the BODE score are independent prognostic 

Discussion

The results of the present longitudinal study revealed that serum CRP concentrations and the BODE score are independent prognostic variables for mortality in patients with stable COPD. The accumu-

The concentration of CRP is also related to the presence of air-

The reason for these conflictive findings can be the different study 

The present study also showed that the concentration was significantly associ-

As the accumulated tests suggest that the mortality in patients 

The in vitro studies have demonstrated that it can activate the 

The in vitro studies have demonstrated that it can activate the 

Fig. 3. The accumulative survival rates of the patients with COPD were classified from the worst to the best in the following manner: serum CRP concentration>3 mg/l and quartile 3–4; serum CRP concentration=3 mg/l and quartile 1–2; serum CRP concentration<3 mg/l and quartile 3–4; serum CRP concentration<3 mg/l and quartile 1–2 (P<.001).

Discriminant function analysis also showed that CRP and the BODE score were signifi-

This indicates that the use of the concentration of this reactive and 

Nevertheless, the conclusions of the study do not coincide with the 

Therefore, the correlation between the serum CRP levels and the 

CRP as well as the BODE score do not correlate and that both are 

CRP is a circulating pentraxin largely, although not exclusively, 

The reason could be the small sample 

The reason for this conflictive findings can be the different study 

Nevertheless, the conclusions of the study do not coincide with the 

The results of the de Torres et al. study demonstrated that the concen-

In spite of the continued controversy 

The present study demonstrates that the combi-

This present study has several limitations. In the first place, we 

CRP values did not correlate with the BODE scores, not even in the 

The population of this latter study included patients with 

Nevertheless, the conclusions of the study do not coincide with the 

In a later study, only BMI and PaO2 were significantly differ-

The reason could be the small sample size with a reduced statistical power. Although, in general, inhaled 

Second of all, some patients treated 

The present study demonstrates that the combi-

In addition, the causes of mortal-

the causes of mortality 

CRP values did not correlate with the BODE scores, not even in the 

In a later study, only BMI and PaO2 were significantly differ-

Nevertheless, the conclusions of the study do not coincide with the 

The results of the present longitudinal study revealed that serum CRP concentrations and the BODE score are independent prognostic variables for mortality in patients with stable COPD. The accumulative survival rates of the COPD patients were classified from the worst to the best in the following manner: serum CRP concentration >3 mg/l and quartile 3–4; serum CRP concentration =3 mg/l and quartile 1–2; serum CRP concentration <3 mg/l and quartile 3–4; serum CRP concentration <3 mg/l and quartile 1–2 (P<.001).
with CRP concentration ≤ 3 mg/l and a BODE score in quartile 1–2. The combination of both precisely predicted the survival of patients with stable COPD. Additional cohort studies with a larger size sample will determine their validity.

**Funding**

The Chang Gung Memorial Hospital provided funding for this study (CMRPG840421).

**Conflict of Interest**

The authors declare having no economic relationships with commercial entities with interests in this topic of research.

**Acknowledgement**

The authors would like to express their gratitude towards C. Y. Lin for helping with the statistical analysis.

**References**


